NasdaqCM:PLSEMedical Equipment
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial
Earlier this month, Pulse Biosciences received FDA Investigational Device Exemption approval to begin its NANOPULSE-AF clinical study of the nPulse Cardiac Catheter Ablation System in up to 145 patients with drug-resistant paroxysmal atrial fibrillation across as many as 30 global sites.
This milestone, supported by ongoing European feasibility experience with 150 patients, moves the company’s nsPFA cardiac platform into a pivotal phase of clinical validation with potential implications for...